Interestingly, two studies that reported the efficacy of erlotinib and bevacizumab conducted exploratory subanalyses of patients with and without pleural or pericardial effusions, factors that predict poor efficacy of first- and second-generation EGFR TKIs.17 Here, EGFR is linked to pericardial effusion.